새로운 퀴놀론계 항균제 DWQ-013의 항균작용

In vitro and in vivo Antibacterial Activities of the New Quinolone, DWQ-013

In vitro and in vivo antibacterial activities of DWQ-013(1-cyclopropyl-6,8-difluoro-7-(3-methylthiomethylpyrrolidinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid), a new fluoroquinolone antibacterial agent, were compared with those of ciprofloxacin, sparfloxacin and ofloxacin against aerobic and anaerobic standard strains and clinical isolates. DWQ-013 had a broad spectrum and potent antibacterial activity against Gram-positive and Gram-negative bacteria. The antibacterial activity of DWQ-013 against Staphylococcus aureus was equal to that of sparfloxacin(SPFX) and superior to those of ciprofloxacin(CPFX). The antibacterial activity against Gram-negative bacteria was slightly lower than those of ciprofloxacin and sparfloxacin. MIC of DWQ-013 against Pseudomonas aeruginosa(0.781- 1.563mcg/ml) was usually equal to that of sparfloxacin(O.781mcg/ml) and was inferior to that of ciprofloxacin(O.098mcg/ml). The number of viable cells was decreased rapidly after addition of DWQ-013 at concentration of 1-2 folds of MIC.